Liver Disease Clinical Trials in San Antonio

Showing 1-20 of 89 trials

A Research Study on Etavopivat in Participants With and Without Liver Disease

NCT06336018

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic function (matched controls). During the study, all participants will be given a single oral dose of etavopivat. All participants will take the etavopivat orally together with water. After dosing, the study will last for 7 to 9 days.

Liver Diseases

Novo Nordisk A/S48 participantsStarted May 2024

Orange, California, United States • Orlando, Florida, United States • Orlando, Florida, United States +2 more locations

Active Not RecruitingPhase 3< 1 mile

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222

This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event.

NASHCirrhosis, Liver

Madrigal Pharmaceuticals, Inc.845 participantsStarted Aug 2022

Birmingham, Alabama, United States • Chandler, Arizona, United States • Peoria, Arizona, United States +113 more locations

A Research Study on Etavopivat in Participants With and Without Liver Disease

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Liver Disease Trials in Other Cities

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Phase 2b Study of GSK4532990 in Adults With NASH

A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

Genetic Collection Protocol

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

An Observational Study of Patients With Chronic Liver Disease

Longitudinal Study of Mitochondrial Hepatopathies

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Liver Cirrhosis Network Cohort Study

Other Conditions in San Antonio